Newswire (Published: Wednesday, January 8, 2020, Received: Wednesday, January 8, 2020, 5:15:21 PM CST)

Word Count: 419

2020 JAN 08 (NewsRx) -- By a News Reporter-Staff News Editor at Cancer Daily -- Researchers detail new data in Oncology - Prostate Cancer. According to news reporting out of Mobile, Alabama, by NewsRx editors, research stated, “Prostate cancer is the mostly commonly diagnosed non-cutaneous malignancy and the second leading cause of cancer-related death affecting men in the United States. Moreover, it disproportionately affects the men of African origin, who exhibit significantly greater incidence and mortality as compared to the men of European origin.”

Financial support for this research came from Foundation for the National Institutes of Health.

Our news journalists obtained a quote from the research from the University of South Alabama, “Since androgens play an important role in the growth of normal prostate and prostate tumors, targeting of androgen signaling has remained a mainstay for the treatment of aggressive prostate cancer. Over the years, multiple approaches have been evaluated to effectively target the androgen signaling pathway that include direct targeting of the androgens, androgen receptor (AR), AR co-regulators or other alternate mechanisms that impact the outcome of androgen signaling. Several of these approaches are currently in clinical practice, while some are still pending further development and clinical evaluation. This remarkable progress has resulted from extensive laboratory, pre-clinical and clinical efforts, and mechanistic learnings from the therapeutic success and failures. In this review, we describe the importance of androgen signaling in prostate cancer biology and advances made over the years to effectively target this signaling pathway.”

According to the news editors, the research concluded: “We also discuss emerging data on the resistance pathways associated with the failure of various androgen signaling-targeted therapies and potential of this knowledge for translation into future therapies for prostate cancer.”

For more information on this research see: Therapies Targeted to Androgen Receptor Signaling Axis in Prostate Cancer: Progress, Challenges, and Hope. Cancers, 2019;12(1):51.

Our news journalists report that additional information may be obtained by contacting S. Saranyutanon, Dept. of Pathology, College of Medicine, University of South Alabama, Mobile, AL 36617, United States. Additional authors for this research include S.K. Srivastava, S. Pai, S. Singh and A.P Singh.

The direct object identifier (DOI) for that additional information is: https://doi.org/10.3390/cancers12010051. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.

(Our reports deliver fact-based news of research and discoveries from around the world.)

Companies

University of South Alabama

Places

North America
United States
Americas
Alabama
Mobile

Subjects

Science and Technology
      Scientific Research
            Medical Research
Health and Wellness
      Medical Conditions and Diseases
            Cancer
                  Prostate Cancer
            Men's Health Issues
                  Prostate Cancer
      Health Sciences
            Medical Research
      Treatments and Therapies